FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

about

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

Item

http://www.wikidata.org/entity/Q49869601

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

@en

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

@nl

type

Item

label

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

@en

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

@nl

prefLabel

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

@en

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

@nl

P1476

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.

@en

P2093

Li Li

http://www.w3.org/2001/XMLSchema#string

Ming-Ju Huang

http://www.w3.org/2001/XMLSchema#string

Qi Wang

http://www.w3.org/2001/XMLSchema#string

Sheng-Bin Liao

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Zhi-Jun Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic organization of the human folate receptor genes on chromosome 11q13

Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.

Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.

A step further in understanding the biology of the folate receptor in ovarian carcinoma.

Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome.

Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells.

Surgical management of recurrent ovarian cancer.

The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis.

Folate-targeted therapies for cancer.

P2888

s13048-018-0387-y

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13048-018-0387-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100995590

http://www.w3.org/2001/XMLSchema#string

P698

29433550

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5809985

http://www.w3.org/2001/XMLSchema#string